GO:0004998 transferrin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004998 transferrin receptor activity is a molecular function defined as the selective binding of transferrin and its delivery into the cell via endocytosis.
• Transferrin is the major iron carrier protein in vertebrates, and the transferrin receptor (TFRC/CD71) is the primary route for cellular iron uptake.
• The transferrin receptor is a homodimeric type II transmembrane glycoprotein that binds diferric transferrin at neutral pH and releases iron in acidic endosomes.
• TFRC is highly expressed on rapidly proliferating cells, including hematopoietic progenitors and many cancer cell types, making it a target for drug delivery and immunotoxins.
• Beyond iron uptake, TFRC has non-canonical signaling roles, including regulation of KLRG1 activity and promotion of breast cancer metastasis via HCK-STAT3-MMP9 signaling.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect transferrin receptor function in iron homeostasis, immunity, and cancer.
Description
Transferrin receptor activity (GO:0004998) is a molecular function that enables cells to acquire iron from the extracellular environment by binding the iron-carrier protein transferrin and internalizing it through endocytosis. This activity is fundamental to vertebrate iron metabolism because transferrin is the major iron transport protein in the bloodstream, and the transferrin receptor (TFRC, also known as CD71) is the principal gateway for iron entry into most cell types. Researchers study this term to understand how cells regulate iron uptake, how proliferating cells satisfy their high iron demand, and how dysregulated receptor activity contributes to disease. The transferrin receptor is also a well-established target for drug delivery across biological barriers and for cytotoxic immunotherapies directed at cancer cells. Recent work has expanded the functional repertoire of TFRC beyond iron transport, revealing roles in immune regulation and metastasis. Because of its central importance, transferrin receptor activity is a frequent subject of CRISPR-based functional genomics studies.
transferrin receptor activity At A Glance
| GO ID | GO:0004998 |
|---|---|
| GO term | transferrin receptor activity |
| Ontology | molecular_function |
| Synonym | none listed |
| Major function | Selective binding of transferrin and its endocytic delivery into the cell |
| Primary gene | TFRC (transferrin receptor 1, CD71) |
| Ligand | Transferrin (iron-loaded diferric transferrin) |
| Cellular context | Plasma membrane and endocytic recycling compartments |
| Physiological role | Cellular iron uptake in vertebrates |
What Is GO:0004998?
According to the Gene Ontology, transferrin receptor activity (GO:0004998) is the molecular function of combining selectively with transferrin and delivering transferrin into the cell via endocytosis. Transferrin is a major iron carrier protein in vertebrates, so this activity effectively mediates cellular iron uptake. The term is classified under molecular_function and has no listed synonyms in QuickGO.
Why Is transferrin receptor activity Important in Cell Biology?
Transferrin receptor activity is essential for cellular iron acquisition and thus for processes ranging from erythropoiesis to DNA synthesis and mitochondrial function. Because iron is required for proliferation, TFRC is highly expressed on activated and malignant cells, making it a diagnostic marker and therapeutic target. The receptor also serves as a portal for delivering therapeutic proteins and antibodies into cells and across barriers such as the blood-brain barrier. Understanding its regulation and non-canonical functions is therefore critical for iron biology, immunology, and oncology.
• Mediates the primary route of iron uptake in vertebrate cells.
• Supports rapid proliferation of hematopoietic progenitors and cancer cells.
• Serves as a target for immunotoxins and antibody-drug conjugates in leukemia and lymphoma.
• Enables transferrin-mediated drug delivery across the blood-brain barrier.
• Regulates immune cell activity through association with KLRG1.
• Promotes breast cancer metastasis via non-canonical HCK-STAT3-MMP9 signaling.
• Is a marker of cellular iron status and a subject of iron metabolism research.
• Provides a model system for studying endocytosis and receptor recycling.
Mechanism, Genes and Research Methods
Transferrin binding and iron delivery
In simple terms: The receptor grabs iron-carrying transferrin and pulls it into the cell.
Transferrin receptor activity begins when the receptor binds diferric transferrin at the cell surface. This binding is selective and occurs at neutral pH, allowing the receptor to capture iron-loaded transferrin from the extracellular environment. The receptor-transferrin complex is then internalized via clathrin-coated pits and delivered to endosomes.
Endosomal iron release and receptor recycling
In simple terms: Inside the cell, acid turns the receptor loose so iron can be used.
Within acidified endosomes, the low pH induces a conformational change that releases iron from transferrin. The iron is transported into the cytoplasm by DMT1, while the receptor-transferrin complex recycles back to the plasma membrane. At the cell surface, transferrin is released and the receptor is ready for another round of binding.
Regulation of receptor expression
In simple terms: Cells adjust how much receptor they make based on how much iron they need.
Transferrin receptor expression is regulated post-transcriptionally by iron regulatory proteins (IRPs) that bind iron-responsive elements (IREs) in the TFRC mRNA. When iron is scarce, IRP binding stabilizes TFRC mRNA and increases receptor synthesis. Conversely, high iron levels reduce receptor expression to prevent iron overload.
Non-canonical signaling functions
In simple terms: The receptor also sends signals that affect immunity and cancer spread.
Beyond iron uptake, TFRC can associate with other proteins to modulate signaling. For example, TFRC association with KLRG1 regulates KLRG1 activity in immune cells. In breast cancer, TFRC promotes metastasis by activating HCK-STAT3-MMP9 signaling independently of its iron transport function.
Key Genes Involved in GO:0004998 transferrin receptor activity
The following genes and proteins are central to transferrin receptor activity and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TFRC | Encodes transferrin receptor 1 (CD71), the primary receptor for transferrin | Main subject of iron uptake and cancer studies |
| TF | Encodes transferrin, the iron carrier ligand | Ligand for receptor binding and drug delivery |
| HFE | Regulates transferrin receptor-mediated iron uptake | Hereditary hemochromatosis research |
| TFR2 | Transferrin receptor 2, involved in iron sensing | Iron homeostasis and liver biology |
| DMT1 | Transports iron out of endosomes after release from transferrin | Iron transport studies |
| IRP1 | Iron regulatory protein that stabilizes TFRC mRNA | Post-transcriptional regulation |
| IRP2 | Iron regulatory protein that stabilizes TFRC mRNA | Iron-sensing mechanisms |
| KLRG1 | Immune receptor that associates with TFRC | Immune regulation studies |
| HCK | Kinase activated by TFRC in breast cancer | Metastasis signaling research |
| STAT3 | Transcription factor downstream of HCK | Cancer signaling |
| MMP9 | Matrix metalloproteinase induced by TFRC signaling | Invasion and metastasis |
| CD71 | Alternative name for transferrin receptor 1 | Flow cytometry marker |
| EPO | Erythropoietin, stimulates erythroid proliferation and iron uptake | Erythropoiesis research |
| GATA1 | Transcription factor regulating erythroid gene expression | Hematopoietic differentiation |
| MYC | Oncogene that promotes proliferation and iron demand | Cancer metabolism |
| HIF1A | Hypoxia-inducible factor regulating iron metabolism genes | Hypoxia response |
| TP53 | Tumor suppressor linked to iron metabolism | Cancer and iron crosstalk |
How Is transferrin receptor activity Regulated?
Transferrin receptor activity is regulated at multiple levels. Post-transcriptionally, iron regulatory proteins (IRP1 and IRP2) bind iron-responsive elements in the TFRC mRNA to stabilize it under low-iron conditions and reduce it when iron is abundant. At the protein level, receptor recycling and degradation are controlled by endosomal sorting and ubiquitination. Signaling pathways such as mTOR and hypoxia-inducible factors can also influence TFRC expression in proliferating cells. Additionally, non-canonical interactions with proteins like KLRG1 modulate receptor function in immune contexts.
transferrin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TFRC | Breast cancer metastasis | TFRC knockout or overexpression in breast cancer cell lines |
| TFRC | Leukemia and lymphoma | Anti-TFRC immunotoxin treatment in hematopoietic progenitor assays |
| HFE | Hereditary hemochromatosis | HFE mutant knock-in mice or cell lines |
| KLRG1 | Immune regulation | KLRG1-TFRC interaction studies in T cells |
| TF | Iron deficiency and drug delivery | Transferrin-conjugated drug uptake assays |
Cancer and metastasis
Transferrin receptor activity is upregulated in many cancers to meet high iron demands for proliferation. In breast cancer, TFRC promotes metastasis through non-canonical activation of HCK-STAT3-MMP9 signaling, independent of iron transport. Targeting TFRC with immunotoxins has shown cytotoxic activity against leukemic progenitors.
Iron overload and hematological disorders
Dysregulated transferrin receptor activity contributes to iron-loading disorders such as hereditary hemochromatosis, where HFE mutations alter receptor-mediated iron uptake. In erythropoiesis, transferrin receptor activity is essential for iron delivery to developing red blood cells.
Neurological and immune disorders
Transferrin receptor-mediated delivery is exploited to cross the blood-brain barrier for therapeutic protein delivery. In immune cells, TFRC association with KLRG1 regulates immune responses, linking receptor activity to immune disorders.
From transferrin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TFRC loss impair iron uptake and proliferation? | TFRC knockout cell lines |
| Does a point mutation in TFRC alter transferrin binding? | TFRC point-mutation knock-in cells |
| Can TFRC be tagged for imaging without losing function? | Tagged TFRC knock-in (e.g., GFP) |
| Does TFRC overexpression drive metastasis? | TFRC overexpression in cancer cell lines |
| Does TFRC interact with KLRG1 in immune cells? | Co-immunoprecipitation in TFRC knockout vs wild-type |
| Can transferrin-conjugated drugs cross the blood-brain barrier? | In vivo models with TFRC-targeted delivery |
How to Study the transferrin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for iron uptake | Identify novel regulators of TFRC |
| Transferrin uptake assay | Receptor-mediated endocytosis | Quantify TFRC activity |
| Co-immunoprecipitation | Protein-protein interactions | Study TFRC-KLRG1 association |
| RNA-seq | Transcriptional changes | Measure TFRC expression under iron stress |
| Western blot | Protein levels | Assess TFRC stability |
| Flow cytometry | Surface TFRC (CD71) levels | Cell surface receptor quantification |
| Immunotoxin cytotoxicity assay | Cell killing via TFRC targeting | Leukemia progenitor studies |
| In vivo delivery assay | Blood-brain barrier transport | TFRC-targeted therapeutic delivery |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes required for transferrin receptor activity and iron uptake, revealing synthetic lethal interactions.
Proteomic and interactomic approaches
Affinity purification coupled to mass spectrometry can map TFRC interaction partners, including KLRG1 and HCK, to understand non-canonical functions.
Imaging and endocytosis assays
Fluorescent transferrin uptake assays and live-cell imaging measure receptor internalization and recycling kinetics.
Transcriptomic and iron-responsive element analysis
RNA-seq and IRE reporter assays assess how iron status regulates TFRC mRNA stability and expression.
How CRISPR Can Be Used to Study GO:0004998 transferrin receptor activity
Knockout
CRISPR knockout of TFRC eliminates transferrin receptor activity, causing iron deficiency and growth arrest in many cell types. This model is used to study iron dependence and to validate TFRC as a therapeutic target.
Point Mutation
Point mutations in the transferrin-binding domain of TFRC can dissect residues required for ligand binding versus endocytosis. Such models help separate iron transport from non-canonical signaling.
Knock-in
Knock-in of tagged TFRC (e.g., GFP or HA) allows real-time imaging of receptor trafficking and interaction studies without altering function. Knock-in of disease-associated mutations can model iron disorders.
Overexpression
Overexpression of TFRC in cancer cell lines increases iron uptake and can promote metastasis through HCK-STAT3-MMP9 signaling. This model is useful for studying TFRC-driven oncogenic pathways.
How EDITGENE Supports transferrin receptor activity Research
Researchers studying transferrin receptor activity-related genes often need to determine whether a candidate gene is causally involved in iron uptake, immune regulation, or cancer progression. EDITGENE provides comprehensive CRISPR services to create precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for transferrin receptor activity research.
Frequently Asked Questions About transferrin receptor activity
What is transferrin receptor activity?
Transferrin receptor activity (GO:0004998) is the molecular function of binding transferrin and delivering it into the cell via endocytosis, thereby mediating iron uptake.
What genes are involved in transferrin receptor activity?
The primary gene is TFRC, which encodes transferrin receptor 1 (CD71). Other involved genes include TF (transferrin), HFE, TFR2, and DMT1.
What is the GO ID for transferrin receptor activity?
The Gene Ontology ID for transferrin receptor activity is GO:0004998.
How does transferrin receptor activity work?
The receptor binds diferric transferrin at the cell surface, internalizes it into endosomes, releases iron in the acidic environment, and recycles back to the membrane.
Why is transferrin receptor activity important in cancer?
Many cancers upregulate TFRC to meet high iron demands for proliferation, and TFRC can promote metastasis through non-canonical signaling.
Can transferrin receptor activity be targeted for drug delivery?
Yes, transferrin receptor-mediated delivery is used to transport therapeutic proteins and antibodies across the blood-brain barrier and into cells.
What diseases are associated with transferrin receptor activity?
Diseases include hereditary hemochromatosis, iron-loading disorders, leukemia, breast cancer metastasis, and immune dysregulation.
How is transferrin receptor activity regulated?
It is regulated post-transcriptionally by iron regulatory proteins (IRPs) that bind iron-responsive elements in TFRC mRNA, and by receptor recycling and degradation.
What CRISPR models are used to study transferrin receptor activity?
Knockout, point mutation, knock-in, and overexpression models in cell lines are commonly used to dissect TFRC function.
What methods measure transferrin receptor activity?
Methods include transferrin uptake assays, flow cytometry for CD71, co-immunoprecipitation, RNA-seq, and CRISPR screens.
Conclusion
Transferrin receptor activity (GO:0004998) is a fundamental molecular function that governs cellular iron uptake and has broad implications in cancer, immunity, and neurological disorders. Its dual role in iron transport and non-canonical signaling makes it a compelling target for both basic research and therapeutic development. CRISPR-based models and functional genomics approaches continue to illuminate its complex biology, offering new opportunities for intervention.
References
- 1. Edavettal S et al.. 2022. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.. Med 3(12):860-882.e15 PMID: 36257298
- 2. Li H et al.. 2002. Transferrin/transferrin receptor-mediated drug delivery.. Med Res Rev 22(3):225-50 PMID: 11933019
- 3. Wouters Y et al.. 2022. VHHs as tools for therapeutic protein delivery to the central nervous system.. Fluids Barriers CNS 19(1):79 PMID: 36192747
- 4. Ponka P. 1999. Cellular iron metabolism.. Kidney Int Suppl 69:S2-11 PMID: 10084280
- 5. Cazzola M et al.. 1991. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.. Cancer Res 51(2):536-41 PMID: 1985771
- 6. Schweier O et al.. 2014. KLRG1 activity is regulated by association with the transferrin receptor.. Eur J Immunol 44(6):1851-6 PMID: 24515870
- 7. Ponka P et al.. 1999. The transferrin receptor: role in health and disease.. Int J Biochem Cell Biol 31(10):1111-37 PMID: 10582342
- 8. Zhao Q et al.. 2026. Non-canonical function of transferrin receptor-1 promotes breast cancer metastasis by activating HCK‒STAT3‒MMP9 signalling.. Clin Transl Med 16(7):e70731 PMID: 42437977
